Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga Cannabis

EXCLUSIVE: How This Company Backed By Deepak Chopra & Tony Robbins Is Disrupting Mental Health With Psychedelics

Doug Drysdale, CEO of Cybin Inc. (NYSE:CYBN) recently joined Javier Hasse and Elliot Lane on the Benzinga Cannabis Insider show.

Cybin, Inc. brings together industry experts from the business and science community working together to bring revolutionary treatment to the mental healthcare landscape.

The executive discussed novel psychedelic treatments for mental health, the investment landscape, BlackRock's support of the company, Tony Robbins and Deepak Chopra's endorsements, and much more.

Click here to watch the show on YouTube.

Earlier this month, the company announced that it had formed a partnership with The Chopra Foundation, a not-for-profit founded by alternative medicine and new age author Deepak Chopra.

"The Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health,” the organization stated in a press release.

A week before that, Cybin announced the granting of a US patent on CYB004, a deuterated version of DMT, which is a psychedelic compound present in an indigenous ceremonial beverage known as ayahuasca. CYB004 is part of the company’s pipeline and is expected to be tested for anxiety disorders and other mental health indications.

"The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” said Deepak Chopra, who serves as the foundation’s chairman of the board and director.

Benzinga’s Cannabis Insider is a live weekly show for cannabis and retail investors where we share with you the major cannabis news, stocks and exclusive interviews.

Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.